• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Mod­er­na woos tri­al vet Melanie Ivars­son to the se­nior R&D team; Ex-Roche CMO San­dra Horn­ing joins Gilead board

6 years ago
Peer Review

Hahn stress­es im­por­tance of da­ta, RWE in first all-hands meet­ing

6 years ago
FDA+

Black Di­a­mond dou­bles in val­ue hours in­to Nas­daq de­but, mark­ing hot start to the 2020 IPO run

6 years ago
Financing

Don't get too ex­cit­ed about Eli Lil­ly's up­com­ing Alzheimer's read­out just yet, R&D chief cau­tions

6 years ago
R&D

Re­sis­tant to CAR-T ther­a­pies? It's the can­cer, not your im­mune sys­tem — study

6 years ago
R&D
Cell/Gene Tx

Doud­na-found­ed CRISPR up­start bags $45M for new Cas re­search, ex­tends its reach in­to ther­a­peu­tics

6 years ago
Financing

With deals in tow, Roche ends 2019 with five dis­card­ed pro­grams

6 years ago
R&D

The sec­ond, first AI de­vel­oped drug en­ters the clin­ic; Aprea gets break­through sta­tus for myelodys­plas­tic syn­dromes ...

6 years ago
News Briefing

Vas Narasimhan wants No­var­tis to have a big fo­cus on Chi­na. Here’s what that looks like

6 years ago
China
Pharma

Eli Lil­ly notch­es an­oth­er pos­i­tive baric­i­tinib eczema tri­al, but has Der­mi­ra made it ob­so­lete?

6 years ago
R&D

Josh Bilenker’s team at Eli Lil­ly chops 3 can­cer drug pro­grams in pipeline cleanup as their $1.6B IL-10 ef­fort ...

6 years ago
R&D

FDA out­lines prod­uct de­vel­op­ment process to com­bat Wuhan coro­n­avirus

6 years ago
FDA+
Coronavirus

Rani Ther­a­peu­tics eyes po­ten­tial IPO as ro­bot­ic pill tech­nol­o­gy takes shape

6 years ago
R&D

Sanofi pol­ish­es rare dis­ease pro­file as Nie­mann-Pick drug scores promis­ing PhII/III da­ta — there's just one ...

6 years ago
R&D

Can­cer-fo­cused Black Di­a­mond vaults on to Nas­daq in $200M+ pub­lic de­but, mark­ing biggest biotech IPO in 2020 so far

6 years ago
Financing

'What's he go­ing to do? He's go­ing to date his wife more!' Steve Holtz­man on Deci­bel and leav­ing biotech (again)

6 years ago
People

The first drug from Eli Lil­ly's new-look on­col­o­gy group gets speedy re­view as Bilenker's team hones fo­cus

6 years ago
R&D

Sanofi stops all but the most ur­gent trips to Chi­na; Flur­ry of or­phan drug des­ig­na­tions ar­rive

6 years ago
News Briefing

No­var­tis re­thinks CML strat­e­gy for next-gen al­losteric drug due for a piv­otal read­out lat­er this year

6 years ago
R&D

What in the world is a MI­NOR CRL, Am­phastar?

6 years ago
R&D
FDA+

Pa­tient dies in a trou­bled HBV drug pro­gram — forc­ing de­vel­op­ers to scrap the drug and shift fo­cus. To STING

6 years ago
R&D

Putting buy­backs on hold, Pfiz­er’s CEO is plot­ting a string of im­por­tant PhII deals in the year ahead. You’ve ...

6 years ago
R&D

How do Amer­i­can sci­en­tists get em­broiled in Chi­na scan­dals? Mof­fitt in­ves­ti­ga­tion sheds some light

6 years ago
People
China

Lau­rence Reid re­turns as CEO of Deci­bel Ther­a­peu­tics — as Steve Holtz­man re­tires

6 years ago
People
First page Previous page 866867868869870871872 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Confirm Profile

Endpoints News